Mirati Therapeutics Inc. has divulged GTPase KRAS (G12S mutant) and/or GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.
TYK Medicines Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently bonded to an EGFR (mutant)-targeting moiety through a linker.
Tumor cell survival is dependent on phosphate homeostasis, which requires high amounts of energy. Researchers have demonstrated that the silencing of xenotropic and polytropic retrovirus receptor 1 (XPR1) led to reduced tumor growth in an ovarian cancer cell line xenograft, and similar vulnerability was found in lung cancer.
Ideaya Biosciences Inc. has exercised its option for an exclusive worldwide license for Biocytogen Pharmaceuticals (Beijing) Co. Ltd.’s B7H3/PTK7 topo-I-payload bispecific antibody-drug conjugate (ADC), BCG-034 (IDE-034), and nominated it as a development candidate.
Prognomiq Inc. secured $34 million in a series D funding round to advance development of an early detection test for lung cancer based on its multiomics platform. The blood-based test could provide an alternative to the underutilized low-dose CT scans currently recommended for individuals at high-risk of lung cancer.
